Can Menopause Increase Libido? Hormones Explained
This is not a replacement for medical care and is intended exclusively for educational purposes. The content provided here does not constitute medical guidance. If you’re experiencing any of these symptoms, we strongly recommend you consult a qualified healthcare provider.
Most articles about menopause and sex drive tell only half the story-the half where desire fades. But can menopause increase libido? For a meaningful subset of women, the honest answer is yes, at least for a period, and understanding why requires looking past the “estrogen drops, desire drops” shorthand into what actually happens to the full hormonal picture.
Large longitudinal studies, including the Study of Women’s Health Across the Nation (SWAN), confirm that average sexual desire does decline across the menopause transition, with the steepest drop around the final menstrual period (Avis et al., Menopause, 2017). But “average” hides real variation. Some women report menopause increased libido rather than diminished it-often tied to relief from contraceptive worry, freedom from periods and PMS, and a hormonal shift more nuanced than “estrogen goes down, so does desire.”
This article walks through both directions honestly: why libido often declines, why it sometimes rises, and what the underlying endocrinology and psychosocial research actually say. It is general education, not a substitute for individualized medical evaluation.
Ready to talk to
a specialist?
Skip the wait, the paperwork, and the referrals.
A certified specialist is ready to see you.
What Large Studies Actually Show About Desire Across Menopause
The SWAN cohort-one of the largest, longest-running studies of the menopause transition-followed thousands of women over more than a decade and found sexual desire, on average, declines independent of age, mood, or overall health changes, with the sharpest decrease clustered around the final menstrual period (Avis et al., Menopause, 2017). Vaginal dryness and pain with intercourse also increased over the same window, though pain and desire did not move in lockstep for every woman.
That said, “on average declines” is a population statistic, not a personal prediction. Within the same dataset, testosterone levels-not estradiol-were the hormone most consistently linked to desire, arousal, and masturbation frequency, a distinction that matters for understanding why “can libido increase during menopause” doesn’t have a single yes-or-no answer (Randolph et al., J Clin Endocrinol Metab, 2015).
Can Menopause Increase Libido? The Hormonal Mechanism Explained
Here is the piece left out of most consumer health content: while estrogen falls sharply at menopause, testosterone and its precursor DHEA decline more gradually, often beginning years earlier on a shallower slope. Because the protein that binds and inactivates testosterone in the bloodstream-sex hormone-binding globulin (SHBG)-tends to fall faster than testosterone itself during the late transition, the proportion of free, biologically active testosterone can actually increase relative to estrogen. One landmark prospective study found the free androgen index rose by roughly 80% between the late transition and early postmenopause (Burger et al., J Clin Endocrinol Metab, 2000).
In practical terms, some women move into a hormonal environment where androgen influence is relatively more prominent than it was premenopausally. Since testosterone is the androgen most associated with desire in the research above, this shift is one plausible explanation for why libido can increase after menopause rather than following the more commonly discussed decline. This is not universal-absolute testosterone still generally trends downward with age-but the ratio shift is real and helps explain the variability across individuals.
Women curious where their own hormone levels stand relative to this pattern may find it useful to discuss comprehensive panels as part of a specialist hormone evaluation, which capture androgens, estradiol, and SHBG together rather than estrogen in isolation.
Why Many Women Also Report Increased Desire for Non-Hormonal Reasons
Endocrinology is only part of the picture. Several psychosocial factors, independent of hormones, are repeatedly identified as contributors to stable or increased desire after menopause:
- Freedom from pregnancy-related anxiety. Once pregnancy is no longer a possibility, some women feel more able to enjoy sex without background worry that previously suppressed desire.
- Relief from PMS and cycle-related symptoms. Fluctuating premenstrual mood, bloating, and irritability can dampen desire cyclically; once cycles stop, this monthly interference disappears for some women.
- Relationship and life-stage factors. Reduced childcare demands, career stabilization, and renewed intimacy can shift the psychosocial context that shapes desire, sometimes for the better.
- General health, mood, and stress levels. A systematic review found relationship quality, mental health, and stress were independently associated with sexual function during the transition-sometimes more strongly than hormone levels alone (Heidari et al., J Menopausal Med, 2019).
A separate longitudinal cohort (Seattle Midlife Women’s Health Study) similarly found higher testosterone and estrone glucuronide correlated with greater desire, while stress, depressed mood, hot flashes, and fatigue were independently associated with lower desire-underscoring that biology and psychology operate together (Woods et al., J Womens Health, 2010).
Why Libido Declines for Many Other Women-and What’s Driving It
For every woman who experiences increased desire, others experience the opposite-decline remains the more statistically common pattern. Several overlapping mechanisms are responsible.
Vasomotor and mood symptoms. Hot flashes, night sweats, disrupted sleep, and mood changes around the transition are independently associated with lower desire, separate from any direct hormonal effect on the sexual response cycle (Woods et al., J Womens Health, 2010).
Genitourinary syndrome of menopause (GSM). Declining estrogen thins vaginal and vulvar tissue, causing dryness, irritation, and pain with penetration. GSM affects a substantial proportion of postmenopausal women and is associated with meaningful reductions in sexual satisfaction, frequency, and quality of life (Faubion et al., Menopause, 2020). Estimates of dyspareunia among affected women vary widely but are consistently reported as common and under-recognized clinically (Wasnik et al., Cureus, 2023).
Declining absolute androgen levels with age. Even though the free androgen ratio may rise relative to estrogen in some women, absolute testosterone and DHEA levels still generally decline with age, which can mean lower desire for women whose androgen decline outpaces any relative shift.
For women navigating either direction, addressing the physical component-especially vaginal tissue health-is often a meaningful first step regardless of whether overall desire has risen or fallen. Some clinicians evaluate this alongside broader hormone strategies, which is one reason a closer look at hormone health can be a useful starting point.
What the Testosterone Therapy Research Shows
Because testosterone shows the most consistent hormonal association with desire, it has become the most studied hormonal intervention for low sexual desire after menopause. A meta-analysis pooling 36 randomized controlled trials (over 8,000 participants) found testosterone therapy was associated with improvements in satisfying sexual events, desire, arousal, pleasure, orgasm, and responsiveness versus placebo (Islam et al., Lancet Diabetes Endocrinol, 201930189-5)).
Based on this evidence, a global consensus statement-endorsed by eleven international endocrine, menopause, and sexual medicine societies-concluded the only evidence-supported indication for testosterone therapy in women is hypoactive sexual desire disorder (HSDD), with a moderate average effect and no government-approved dosage form for women in most countries (Davis et al., Maturitas, 2019). ISSWSH has since published a clinical practice guideline for how candidates should be identified, tested, and monitored if systemic testosterone is considered (Parish et al., J Sex Med, 2021).
This is why a woman noticing either a decline or an unexpected increase in libido may benefit from a personalized hormone evaluation rather than guesswork-self-diagnosing without lab confirmation is unreliable given how many variables (androgens, SHBG, estradiol, thyroid, mood, relationship factors) interact.
When It May Be Worth Discussing With a Specialist
Because desire changes at menopause can stem from hormonal shifts, GSM, mood, or relationship dynamics-or a combination-a structured evaluation is often more informative than assuming a single cause. Women considering a closer look may want to discuss:
- A comprehensive hormone panel (testosterone, free androgen index, estradiol, SHBG, DHEA-S, thyroid) rather than estrogen alone
- Screening for GSM symptoms, which are common but frequently under-reported to clinicians
- Mood, sleep, and stress factors that independently affect desire regardless of hormone status
- Whether evidence-based therapies, including those in the testosterone guidelines above, fit the individual’s specific findings
Key Takeaways
- The answer to can menopause increase libido is yes for some women, even though population averages show an overall decline in desire across the transition (Avis et al., Menopause, 2017).
- Testosterone, not estrogen, is the hormone most consistently linked to sexual desire in large cohort studies (Randolph et al., J Clin Endocrinol Metab, 2015).
- A relative rise in free testosterone versus estrogen during the late transition is one plausible mechanism behind menopause increased libido in some women (Burger et al., J Clin Endocrinol Metab, 2000).
- Freedom from pregnancy concerns, relief from PMS, relationship quality, and reduced stress also help explain why libido can increase after menopause for reasons unrelated to hormones alone (Heidari et al., J Menopausal Med, 2019).
- GSM, vasomotor symptoms, and mood disruption remain common reasons desire declines for many other women during the same period (Faubion et al., Menopause, 2020).
- Testosterone therapy is a moderately effective, evidence-based option specifically for hypoactive sexual desire disorder in postmenopausal women, under specialist guidance (Islam et al., Lancet Diabetes Endocrinol, 201930189-5)).
- Because both increases and decreases in desire have legitimate biological explanations, comprehensive hormone testing-rather than assumption-is the most reliable way to understand an individual pattern.
Frequently Asked Questions
Yes. While population studies show average sexual desire declines across the transition, a meaningful subset of women report stable or increased desire, often linked to shifts in free testosterone, relief from pregnancy concerns, or improved relationship circumstances (Avis et al., Menopause, 2017).
Some women report this, and it may relate to the free androgen index rising relative to estrogen in the late transition and early postmenopause, alongside factors such as reduced parenting stress or freedom from monthly PMS symptoms (Burger et al., J Clin Endocrinol Metab, 2000).
Both patterns are reported. Hormone trajectories vary between individuals, and desire changes aren’t confined strictly to before or after the final menstrual period; some women notice shifts during the perimenopausal fluctuation itself.
Because on average, across large cohorts like SWAN, sexual desire does decline around the final menstrual period, and genitourinary symptoms such as dryness and pain are common and well documented (Faubion et al., Menopause, 2020). Population averages simply don’t capture individual variation.
Testosterone appears to be the hormone most consistently associated with sexual desire in menopause research, and a relative rise in free testosterone versus estrogen is one plausible contributor for women who notice increased desire (Randolph et al., J Clin Endocrinol Metab, 2015).
Not necessarily. GSM is strongly associated with reduced sexual satisfaction and pain during intercourse for many women (Wasnik et al., Cureus, 2023), but some longitudinal analyses found vaginal dryness was not independently associated with lower desire itself, suggesting it affects comfort more than baseline desire (Woods et al., J Womens Health, 2010).
Global specialty consensus supports testosterone therapy as an evidence-based option specifically for HSDD in postmenopausal women, though no government-approved dosage form for women exists in most countries and treatment should follow clinical guideline protocols under specialist supervision (Davis et al., Maturitas, 2019). Curious what your own hormone picture looks like during this transition? Explore UBERDOC’s menopause support to discuss comprehensive, personalized testing with a specialist.
References
- Avis NE, Colvin A, Karlamangla AS, Crawford S, Hess R, Waetjen LE, Brooks M, Tepper PG, Greendale GA. Change in sexual functioning over the menopause transition: results from the Study of Women’s Health Across the Nation (SWAN). Menopause, 2017; 24(4):379–390. DOI: https://doi.org/10.1097/GME.0000000000000770
- Randolph JF Jr, Zheng H, Avis NE, Greendale GA, Harlow SD. Masturbation frequency and sexual function domains are associated with serum reproductive hormone levels across the menopausal transition. Journal of Clinical Endocrinology & Metabolism, 2015; 100(1):258–266. DOI: https://doi.org/10.1210/jc.2014-1725
- Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper JL. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. Journal of Clinical Endocrinology & Metabolism, 2000; 85(8):2832–2838. DOI: https://doi.org/10.1210/jcem.85.8.6740
- Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes & Endocrinology, 2019; 7(10):754–766. DOI: https://doi.org/10.1016/S2213-8587(19)30189-530189-5)
- Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J, Parish SJ, Pinkerton J, Rymer J, Simon JA, Vignozzi L, Wierman ME. Global Consensus Position Statement on the use of testosterone therapy for women. Maturitas, 2019; 128:89–93. DOI: https://doi.org/10.1016/j.maturitas.2019.07.001
- Parish SJ, Simon JA, Davis SR, Giraldi A, Goldstein I, Goldstein SW, Kim NN, Kingsberg SA, Morgentaler A, Nappi RE, Park K, Stuenkel CA, Traish AM, Vignozzi L. International Society for the Study of Women’s Sexual Health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. Journal of Sexual Medicine, 2021; 18(5):849–867. DOI: https://doi.org/10.1016/j.jsxm.2020.10.009
- Faubion SS, Kingsberg SA, Clark AL, et al. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause, 2020; 27(9):976–992. DOI: https://doi.org/10.1097/GME.0000000000001609
- Wasnik VB, Acharya N, Mohammad S. Genitourinary syndrome of menopause: a narrative review focusing on its effects on the sexual health and quality of life of women. Cureus, 2023; 15(11):e48143. DOI: https://doi.org/10.7759/cureus.48143
- Woods NF, Mitchell ES, Smith-DiJulio K. Sexual desire during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women’s Health Study. Journal of Women’s Health, 2010; 19(2):209–218. DOI: https://doi.org/10.1089/jwh.2009.1388
- Heidari M, Ghodusi M, Rezaei P, Kabirian Abyaneh S, Heidari Sureshjani E, Sheikhi RA. Sexual function and factors affecting menopause: a systematic review. Journal of Menopausal Medicine, 2019; 25(1):15–27. DOI: https://doi.org/10.6118/jmm.2019.25.1.15
Ready to talk to
a specialist?
Skip the wait, the paperwork, and the referrals.
A certified specialist is ready to see you.
